Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warm winter cools Prestige sales

This article was originally published in The Tan Sheet

Executive Summary

Low demand for cold and flu products continued to slow Prestige Brands' sales during its fiscal 2007 fourth quarter, but sales of Wartner wart treatment products it acquired in September 2006 prevented a larger slide and the firm looks for a sales boost this year from a Murine brand line extension. In a May 9 earnings release, the Irvington, N.Y.-based firm said its sales fell 2% to $78 mil. in the January-March period. During a same-day earnings call, Chairman and CEO Mark Pettie said the low demand in the firm's third quarter for cold and flu products continued in its latest quarter (1"The Tan Sheet," Feb. 12, 2007, p. 5). OTC sales were down 3% to $43.3 mil., with Chloraseptic sales dropping 20% and Little Remedies 9%, Pettie added. In the first half of its fiscal 2008, Prestige will launch a Murine aerosol product for preventing ear wax buildup and target initial marketing for people with chronic problems, he said...

You may also be interested in...



Sales & Earnings In Brief

GSK on consumer division profitability: "Some of you would like us to sell" the GlaxoSmithKline Consumer Healthcare business, CEO J.P. Garnier said to analysts during a year-end earnings call for the firm Feb. 8. "Remember, if we sell it as a standalone, the consumer healthcare profit margin will drop like lead, because we will lose all the synergies that exist," he commented. "It's artificially very, very profitable .... the value of the enterprise as a standalone in my view is less than incorporating to the group, jut simply on the cost synergies." Garnier also pointed to the "benefits of Rx product switching and being passed on and being prolonged by our consumer healthcare enterprise." Sales for the consumer unit increased 9% in the fourth quarter to $1.62 bil. (£= $1.97) and 6% for the full year to $6.09 bil. OTC medicine sales grew 5% for the full year over 2005, while Oral Care saw a 6% sales increase to $1.29 bil...

Herbalife 'Just Getting Started' On Growth Following Flat 2019 At $4.9bn Net Sales

"We're a growth company, well-positioned in a global trend of nutrition that the world hasn't seen before," says co-president John Agwunobi. But the direct seller's record volume increase in 2019 didn’t translate to revenue growth as China, Mexico and Central and South America pulled down results.

US FDA Tech Modernization Plan’s Costs Uncertain

Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.

Topics

UsernamePublicRestriction

Register

PS100513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel